GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhejiang Cheng Yi Pharmaceutical Co 603811.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

6.65

-1.19%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Zhejiang Cheng Yi Pharmaceutical Co

Its shares trade on Shanghai under the ticker 603811.SS. It has been listed since 15 March 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥812.3m and net income of CN¥195.1m. At that date it held total assets of CN¥1.70bn and shareholders' equity of CN¥1.39bn.

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical drugs and preparations of raw materials. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2017-03-15. The Company’s products are on the spectrum from arthritis, dieresis to anti-virus and anti-tumor. The main products include bulk pharmaceutical chemicals, injections, capsules, intermediates and others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
15 Mar 2017
Employees
746

Leadership

Pay as last reported

  • Mr. Yiyi YanChairman of the Board, since 2019
  • Mr. Bingjun RenVice Chairman of the Board, since 2019
  • Mr. Sunzhan LuChief Financial Officer
  • Mr. Chunjian ZhaoGeneral Manager, Director, since 2019
  • Ms. Zehui KeDeputy General Manager, Secretary of the Board
  • Mr. Shisheng LiDeputy General Manager, Director, since 2019
  • Mr. Zhidong LuDeputy General Manager
  • Mr. Zhihong ZhangDeputy General Manager

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Shanghai with 746 employees
  • Engages in R&D, production, and sale of chemical drugs
  • Products include bulk pharmaceutical chemicals and injections

Weaknesses

  • No specific market share or revenue figures provided
  • Limited product range described as 'on the spectrum from arthritis to anti-tumor'
  • No mention of international presence or expansion plans

Opportunities

  • Potential growth in pharmaceutical sector in China
  • IPO in 2017 may provide capital for expansion
  • Diverse product portfolio including anti-virus and anti-tumor

Threats

  • Untrusted source description may contain inaccuracies
  • No information on competitive landscape or market challenges
  • Dependence on domestic market without international diversification

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.